Nuformix PLC
LSE:NFX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Japan Prime Realty Investment Corp
TSE:8955
|
JP |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| UK |
|
Nuformix PLC
LSE:NFX
|
4.7m GBP |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Nuformix PLC
Glance View
Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. The company is headquartered in Cambridge, Cambridgeshire and currently employs 3 full-time employees. The company went IPO on 2015-12-17. The firm focuses on medical needs in fibrosis and oncology using drug repurposing. Its clinical pipeline includes NXP001, NXP002 and NXP004. NXP001, is a form of the drug aprepitant that is marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting). NXP002, is its pre-clinical lead asset and used for inhaled treatment for idiopathic pulmonary fibrosis (IPF). NXP004, is an oncology drug that is used for the treatment of several cancers. The firm's subsidiary is Nuformix Technologies Limited.
